
Press Releases
Presentations & Publications >
|
INTARCIA PRESENTATIONS & PUBLICATIONS
|
| Jun 28, 2010 |
Comparing ITCA 650, Continuous Subcutaneous Delivery of Exenatide Via DUROSĀ® Device, vs Twice Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
|
| Nov 06, 2009 |
Stability of ITCA 650 for Continuous Subcutaneous Delivery of Exenative at Body Temperature for 12 Months |
| Nov 06, 2009 |
Continuous Subcutaneous Delivery of Exenative via ITCA 650 Lowers Plasma Glucose, HbA1c and Reduces Weight in a 28-day Phase 1b Study in Type 2 Diabetes |
| Sept 30, 2009 |
ESAD Presentation: A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS® Device Lowers Fasting and Postprandial Plasma Glucose |
| Jun 06, 2009 |
ADA 2009 Late Breaker:
A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS® Device Lowers Fasting and Postprandial Plasma Glucose
|
| Nov 18, 2008 |
Intarcia Therapeutics, Inc. Presents DUROS® Delivery of Hepatitis C and type 2 diabetes therapies at AAPS conference
|
| May 01, 2008 |
DUROS® Technology Delivers Pepties and Proteins at Consistent Rate Continuously for 3 to 12 Months
|
|